Welcome to our dedicated page for Steris news (Ticker: STE), a resource for investors and traders seeking the latest updates and insights on Steris stock.
STERIS plc provides healthcare and life sciences products and services that support patient care, with an emphasis on infection prevention. Its recurring news includes financial results and outlook updates for continuing operations, quarterly dividend actions, conference-call announcements, and board or executive governance changes.
The company’s business updates center on sterilization services, Applied Sterilization Technologies, sterilizers, washer-disinfectors, and decontamination equipment and supplies used by care providers and biopharma manufacturing sites. Corporate announcements also address capital spending, cash flow expectations, and shareholder distribution information.
STERIS (NYSE: STE) reported fiscal 2026 revenue from continuing operations up 9% to $5.9 billion, with constant currency organic growth of 7%. Diluted EPS from continuing operations rose to $7.93, and adjusted EPS increased to $10.17. Free cash flow reached $982.9 million.
For fiscal 2027, STERIS expects revenue growth of 7–8% and adjusted EPS of $11.10–$11.30. The Board approved a new $1 billion share repurchase program and plans about $375 million in capital expenditures, including a new Mentor, Ohio manufacturing plant.
STERIS (NYSE: STE) appointed Pierre Boulud to its Board of Directors effective May 5, 2026. Boulud is CEO of bioMérieux since 2023 and previously served as bioMérieux COO and head of Asia Pacific; he spent 14 years at Ipsen and earlier worked at Boston Consulting Group.
The company emphasized his leadership, global perspective, strategic acumen, and operational expertise as reasons for the appointment.
STERIS (NYSE: STE) announced a quarterly dividend of $0.63 per share. The dividend is payable on June 26, 2026 to shareholders of record at the close of business on June 8, 2026. The company provides U.S. tax guidance and Forms 8937 on its investor website.
Contact: Julie Winter, Vice President, Investor Relations and Corporate Communications.
STERIS (NYSE: STE) will host a conference call to discuss fiscal 2026 fourth quarter and full year results at 9:00 a.m. ET on May 12, 2026.
A press release with financial results will be issued after U.S. market close on May 11, 2026. Live webcast and replay details, phone numbers, and access codes are provided for investor access.
Teleflex (NYSE:TFX) announced Board and governance changes on April 9, 2026, including the nomination of Michael J. Tokich as an independent director and the appointment of Andrew A. Krakauer as Chairman effective after the 2026 Annual Meeting.
The Board will form a Growth and Operating Committee to support transformation efforts, and the company plans to commence opportunistic share repurchases under its existing $1 billion authorization beginning in Q2 2026, subject to market conditions and cash flow needs.
STERIS (NYSE: STE) reported fiscal 2026 third-quarter continuing‑operations revenue of $1.5 billion, up 9% year‑over‑year, with constant currency organic growth of 8%. As‑reported EPS was $1.96; adjusted EPS was $2.53. Nine‑month free cash flow reached $737.6 million. Fiscal 2026 outlook was maintained, with adjusted EPS guidance of $10.15–$10.30 and revenue growth of 8–9%.
STERIS (NYSE: STE) announced a quarterly cash dividend of $0.63 per share, payable March 19, 2026, to shareholders of record at the close of business on February 17, 2026.
The company provided guidance on U.S. tax treatment and referenced Forms 8937 for additional tax information.
STERIS (NYSE: STE) will host a conference call to discuss its fiscal 2026 third quarter results at 9:00 a.m. ET on February 5, 2026. A related press release with financial results will be issued after U.S. market close on February 4, 2026. Investors can listen live at www.steris-ir.com or by phone at 1-833-535-2199 (U.S.) or 1-412-902-6776 (international). A replay will be available beginning 12:00 p.m. ET on February 5, 2026 at www.steris-ir.com or by phone using access code 7731965 (U.S. replay dial-in: 1-855-669-9658; international replay: 1-412-317-0088).
Mettler-Toledo (NYSE: MTD) announced that Michael J. Tokich will join its Board of Directors, effective February 5, 2026. Mr. Tokich served more than 17 years as Senior Vice President and Chief Financial Officer at STERIS and recently transitioned to Senior Financial Advisor at STERIS. He joined STERIS in 2000 and became CFO in 2008. Board Chair Roland Diggelmann highlighted Tokich’s nearly two decades of U.S. public company CFO experience and said his financial, operational, and IT expertise will add value to Mettler-Toledo’s oversight. The company reiterated its global leadership in precision instruments and broad sales and service network across approximately 40 direct-presence countries.
STERIS (NYSE: STE) reported fiscal 2026 second quarter results: total revenue $1.5B (+10% YoY) and constant-currency organic revenue +9%. As-reported EPS from continuing operations was $1.94; adjusted EPS $2.47 vs $2.14 year-ago. Segment performance: Healthcare revenue $1,033.8M (+9%), AST $281.5M (+10%) with a 76% decline in capital equipment, and Life Sciences $145.0M (+13%).
Cash: H1 operating cash $707.8M and free cash flow $527.7M (H1). Company raised fiscal 2026 guidance: constant-currency organic revenue now +7–8%, adjusted EPS $10.15–10.30, and free cash flow ~ $850M; tariffs still estimated to cut pre-tax profit by ~$45M and effective tax rate ~24%.